Sun Pharmaceutical Industries Ltd. experienced a 2.43% decline in its share price on Friday, May 23, 2026, closing at Rs 1,845.20 apiece on the BSE following the announcement of its Q4FY26 earnings. This dip occurred despite the stock hitting a 52-week high of Rs 1,917.15 earlier in the week on Tuesday, May 19, 2026. The counter currently trades less than 4% below its record peak.
Q4 Performance Overview
The company reported an 118 basis point improvement in its gross margin during the fourth quarter of fiscal year 2026. However, this positive development was largely counteracted by increased operational expenses across staff, selling, general & administrative (SG&A), and research & development (R&D) segments. The brokerage noted that EBITDA grew 3% year-over-year despite a 13% sales growth, attributing the offset to these higher costs.
Analyst Outlook and Target Price
Following the Q4 results, domestic brokerage HDFC Securities reaffirmed its 'Buy' rating for Sun Pharma's stock. The brokerage also upgraded its target price to Rs 2,120 per share, an increase from its previous target of Rs 2,000. This revised target suggests a significant upside from current levels, reflecting confidence in the company's future performance.
Key Growth Drivers and Future Prospects
HDFC Securities anticipates sustained growth momentum, particularly within Sun Pharma's specialty business. Key products such as Ilumya, Cequa, and Winlevi are expected to drive this traction. Furthermore, the domestic market is poised for a potential catalyst with the anticipated launch of the diabetes drug Semaglutide (GLP-1). The oral solid form of this drug has completed clinical studies and is currently awaiting approval in India.
Looking ahead to FY27, Sun Pharma's management has projected high-single-digit revenue growth. R&D investments are expected to remain consistent, accounting for 6-7% of sales. Analysts predict that the scaling up of the specialty segment and the India business, fueled by new launches and in-licensing agreements, will effectively offset any softness in the US generics business.
Challenges and Catalysts
A significant factor for a turnaround in the US generics business hinges on key plant clearances for facilities in Halol, Baska, and Mohali. Successful clearances could further bolster the company's performance in this crucial market.